Q3 EPS Estimates for Teladoc Health Decreased by Analyst

Teladoc Health, Inc. (NYSE:TDOC) – Investment analysts at Zacks Research decreased their Q3 2026 earnings per share estimates for Teladoc Health in a research report issued on Wednesday, August 19th. Zacks Research analyst Team now expects that the health services provider will post earnings per share of ($0.21) for the quarter, down from their prior estimate of ($0.20). The consensus estimate for Teladoc Health’s current full-year earnings is ($0.89) per share. Zacks Research also issued estimates for Teladoc Health’s Q4 2026 earnings at ($0.12) EPS, FY2026 earnings at ($0.89) EPS, Q1 2027 earnings at ($0.26) EPS, Q2 2027 earnings at ($0.24) EPS, Q3 2027 earnings at ($0.26) EPS, Q4 2027 earnings at ($0.23) EPS, FY2027 earnings at ($0.98) EPS, Q1 2028 earnings at ($0.14) EPS and Q2 2028 earnings at ($0.21) EPS.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings data on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.04. The business had revenue of $606.93 million during the quarter, compared to the consensus estimate of $615.44 million. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. The company’s quarterly revenue was down 4.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.19) earnings per share. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS.

Other analysts have also issued reports about the stock. Bank of America upped their price target on shares of Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Citigroup dropped their target price on Teladoc Health from $11.00 to $7.50 and set a “neutral” rating on the stock in a report on Monday, August 3rd. Canaccord Genuity Group cut their target price on Teladoc Health from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teladoc Health in a research note on Wednesday. Five analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $7.54.

Teladoc Health Trading Down 2.7%

Teladoc Health stock opened at $6.48 on Friday. Teladoc Health has a 52 week low of $4.40 and a 52 week high of $9.89. The stock has a market cap of $1.18 billion, a price-to-earnings ratio of -6.55 and a beta of 2.12. The company’s 50-day moving average price is $8.10 and its two-hundred day moving average price is $6.59.

Insider Buying and Selling

In other Teladoc Health news, insider Fernando M. Rodrigues sold 5,677 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total transaction of $43,315.51. Following the sale, the insider owned 9,572 shares in the company, valued at approximately $73,034.36. The trade was a 37.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Adam C. Vandervoort sold 7,906 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total transaction of $60,322.78. Following the sale, the insider owned 110,261 shares in the company, valued at $841,291.43. This represents a 6.69% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 39,195 shares of company stock worth $299,058. Company insiders own 0.70% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Proficio Capital Partners LLC acquired a new position in shares of Teladoc Health in the 2nd quarter valued at about $106,000. Two Sigma Securities LLC bought a new stake in Teladoc Health in the second quarter worth approximately $290,000. Pin Oak Investment Advisors Inc. acquired a new position in shares of Teladoc Health during the 2nd quarter worth $186,000. Twin Lakes Capital Management LLC acquired a new stake in shares of Teladoc Health in the 2nd quarter valued at $26,000. Finally, Empowered Funds LLC bought a new stake in Teladoc Health in the second quarter worth $5,765,000. Hedge funds and other institutional investors own 76.82% of the company’s stock.

Key Stories Impacting Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Improved full-year earnings outlook: Zacks Research raised its FY2026 EPS forecast to a loss of $0.89 from $0.96 and its FY2027 forecast to a loss of $0.98 from $1.04. Estimates for Q4 2026, Q1 2027, Q2 2027, Q3 2027, Q4 2027 and Q1 2028 also improved modestly. The revisions suggest somewhat better expected cost control or operating performance, although Teladoc is still projected to remain unprofitable. Teladoc Health analyst estimates
• Neutral Sentiment: Near-term estimates remain broadly unchanged: Zacks maintained its full-year 2026 loss estimate at $0.89 per share, in line with consensus. Teladoc’s stock opened at $6.48, below its 50-day moving average of $8.10 and close to its 200-day average of $6.59, reflecting continued investor caution around the company’s profitability and growth prospects.
• Negative Sentiment: Some quarterly forecasts worsened: Zacks reduced its Q3 2026 EPS forecast to a loss of $0.21 from $0.20 and lowered its Q2 2028 estimate to a loss of $0.21 from $0.20. These changes point to continued uncertainty about the pace of earnings improvement.
• Negative Sentiment: Investor investigation announced: Pomerantz LLP said it is investigating potential claims on behalf of Teladoc investors. Although the announcement does not establish wrongdoing, such investigations can increase legal and reputational concerns and weigh on sentiment. Pomerantz investor alert

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.